Drug General Information (ID: DDIA8X3P2Q)
Drug Name			Valrubicin		Drug Info		Hexaminolevulinate		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Malignancy Photosensitizers
Structure

Mechanism of Valrubicin-Hexaminolevulinate Interaction (Severity Level: Major)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Valrubicin				Hexaminolevulinate
Mechanism		Interfere with the diagnostic effect of hexaminolevulinate				Hexaminolevulinate
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Hexaminolevulinate when combined with Valrubicin

Recommended Action
Management		The use of hexaminolevulinate is considered contraindicated in patients given BCG immunotherapy or intravesical chemotherapy within the past 90 days due to a high risk of bladder inflammation in these patients. Widespread inflammation of the bladder should be excluded by cystoscopy before hexaminolevulinate is administered. If a widespread inflammation in the bladder becomes evident during white light inspection, the blue light inspection should be avoided.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Cysview (hexaminolevulinate). Photocure Inc, Princeton, NJ.